<DOC>
	<DOCNO>NCT00098059</DOCNO>
	<brief_summary>This study evaluate safety blood level new pediatric formulation Famvir child 1-12 year age . In Part A , patient receive single dose famciclovir ( 12.5 mg/kg ) ass pharmacokinetics ( PK ) safety . In Part B , patient receive multiple dos famciclovir alone concomitant oral anti-herpes therapy ass safety tolerability . Part B start PK data Part A analyzed .</brief_summary>
	<brief_title>Famciclovir Pediatric Formulation Children 1 12 Years Age With Herpes Simplex Infection</brief_title>
	<detailed_description />
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Famciclovir</mesh_term>
	<mesh_term>2-Aminopurine</mesh_term>
	<criteria>History laboratory evidence herpes simplex infection Clinical evidence suspicion herpes simplex infection Patients unable swallow Concomitant use probenecid Positive pregnancy test Additional protocoldefined inclusion/exclusion criterion may apply . For detailed information eligibility , please contact study center near call follow number : 18627783544 14349513228</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>herpes simplex</keyword>
	<keyword>cold sore</keyword>
	<keyword>fever blister</keyword>
	<keyword>child</keyword>
	<keyword>Famvir</keyword>
	<keyword>famciclovir</keyword>
</DOC>